News | January 4, 2019

Biosimilar Monoclonal Antibodies Market To Witness Double Digit CAGR Of 35.7% By 2026

Biosimilar Monoclonal Antibiotics market expressed US$ 1,516.9 Mn in 2016 with the CAGR of 35.70%, thus growth period of this market can be stated as from 2018-2027. According to a latest study report published by the MarketResearch.Biz, the global Biosimilar Monoclonal Antibiotics market is booming and expected to gain eminence over the forecast period. The market is forecasted to demonstrate a spectacular growth by 2027, surpassing its previous growth records in terms of value with a prominent CAGR during the anticipated period (2018 – 2027).

"Global Biosimilar Monoclonal Antibiotics Market by Segmentation, Revenue, Growth Ratio, Manufacturers, Regions Forecast to 2026" Projected to Grow Radiantly By 2027

A monoclonal antibody is a laboratory-made protein that can bind to substances in the body such as cancer cells. It is made in such a way that it binds to only one substance to treat a specific type of cancer. Different monoclonal antibodies are required to be made to target different types of cancers as each monoclonal antibody recognizes their respective protein and work in different ways, depending on the protein they are targeting.

You Can Browse Full Report @:

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Allergan plc, BIOCADBioXpress, Therapeutics SA, Biocon, Boehringer Ingelheim GmbH, Celltrion Inc, Coherus BioSciences Inc, Dr. Reddys Laboratories Ltd., Genor BioPharma Co Ltd, Intas Pharmaceuticals Limited, Novartis AG, Pfizer Inc, Reliance Life Sciences.

The Global Biosurgery Market has been segmented as below:
Global biosimilar monoclonal antibodies market segmentation by drug class: Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab. Global biosimilar monoclonal antibodies market segmentation by application: Oncology, Chronic and Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Others

On the basis of drug class segmentation, Adalimumab segment is estimated to account for major revenue share in the global market and is projected to register highest CAGR of around 37.0% over the forecast period. Also, the Abciximab segment is anticipated to register lowest CAGR of around 33.0%, as compared to the other drug class segments in the global biosimilar monoclonal antibodies market.

Among the application segments, the oncology segment accounted for highest revenue share in the global biosimilar monoclonal antibodies market, and is expected to register highest CAGR of around 38.0% during the forecast period 2017 & 2026. The chronic and autoimmune diseases segment is projected to account for second-highest revenue share contribution in the global market, and register a CAGR of around 35.0% over the forecast period.

Request Free Sample Copy Of The Research @

Regional Analysis:
Regional study struggling in the Biosimilar Monoclonal Antibiotics market includes Europe (Germany, France, Russia, UK, and Italy)Biosimilar Monoclonal Antibiotics market, North America Biosimilar Monoclonal Antibiotics market (Canada, Mexico, and the USA), South America (Argentina and Brazil), Biosimilar Monoclonal Antibiotics market in Asia-Pacific (China, South Korea, Thailand, India, Vietnam, Malaysia, Indonesia, and Japan), The Middle East and Africa (South Africa, Saudi Arabia, Egypt and Nigeria) Biosimilar Monoclonal Antibiotics market respectively.

The market in the Americas dominated the global biosimilar monoclonal antibodies market in revenue terms, and is estimated to account for largest market revenue contribution of US$ 618.4 million in 2017 as compared to that of markets in other regions.

Target Audience:

* Biosimilar Monoclonal Antibiotics and Related Manufacturing Industries

* Suppliers and Traders of Biosimilar Monoclonal Antibiotics

* Academic Centers

* Research institutes, organizations, and consulting companies